The DOI matches its Crossref record.
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
Open accessAbstract
In Bihar, India, where visceral leishmaniasis is hyperendemic, amphotericin B deoxycholate is now first-line parenteral treatment. To test the efficacy of amphotericin B deoxycholate versus that of its lipid formulations, Indian patients were randomized to receive treatment with amphotericin B deoxycholate (1 mg/kg on alternate days for 30 days; n=51), liposomal amphotericin B (2 mg/kg per day for 5 days; n=51), or amphotericin B lipid complex (2 mg/kg per day for 5 days; n=51). Infusion-associated reactions were frequent and persistent in subjects treated with amphotericin B deoxycholate. The illness of 3 patients failed to respond to treatment, and 5 patients experienced relapse. Final cure rates were similar. Estimated total treatment costs for a 25-kg patient-417 dollars for amphotericin B deoxycholate, 872 dollars for liposomal amphotericin B, and 947 dollars for amphotericin B lipid complex-differed as a result of drug cost. Substantial reductions (approximately 60%) in the price of liposomal amphotericin B and amphotericin B lipid complex would make treatment costs comparable to that of amphotericin B deoxycholate, permitting administration of short-course regimens in India.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Murray, H. W., Berman, J. D., Davies, C. R., & Saravia, N. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67629-5 · Cited by 1,771
Self-citationAronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E. M., Ephros, M., Jeronimo, S., & Magill, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw670 · Cited by 458
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 434
Self-citationBern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507530 · Cited by 345
Self-citationAronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E., Ephros, M., Jeronimo, S., & Magill, A. (2017) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-84256 · Cited by 338
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L. (2012) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2012.01.003 · Cited by 294
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
Kingsley, J. D., Dou, H., Morehead, J., Rabinow, B., Gendelman, H. E., & Destache, C. J. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9032-4 · Cited by 280
Why nanoparticles prefer liver macrophage cell uptake in vivo
Ngo, W., Ahmed, S., Blackadar, C., Bussin, B., Ji, Q., Mladjenovic, S. M., Sepahi, Z., & Chan, W. C. W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114238 · Cited by 256
Liposomal amphotericin B and leishmaniasis: Dose and response
Sundar, S., & Chakravarty, J. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62886 · Cited by 217
Self-citation
Metadata
- Authors
- Sundar, S., Mehta, H., Suresh, A. V., Singh, S. P., Rai, M., & Murray, H. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-02
- Volume
- 38
- Issue
- 3
- Pages
- 377-383
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2138933525
- Cited by
- 189
- References
- 0
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.